Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Conn PJ, Lindsley CW, Meiler J, Niswender CM (2014) Nat Rev Drug Discov 13: 692-708 Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Ramamoorthy S, Blakely RD (1999) Science 285: 763-6 Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Conn PJ, Jones CK, Lindsley CW (2009) Trends Pharmacol Sci 30: 148-55 Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW (2012) J Med Chem 55: 1445-64 Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW (2014) J Med Chem 57: 10192-7 Total synthesis and biological evaluation of phidianidines A and B uncovers unique pharmacological profiles at CNS targets. Brogan JT, Stoops SL, Lindsley CW (2012) ACS Chem Neurosci 3: 658-64 Sigma-1 receptors: potential targets for the treatment of substance abuse. Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR (2012) Curr Pharm Des 18: 902-19 Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Panarese JD, Cho HP, Adams JJ, Nance KD, Garcia-Barrantes PM, Chang S, Morrison RD, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26: 3822-5
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.